The research indicates that this could be down to Sanofi’s numerous mergers acquisitions over the past decade and it is expected the French pharma will hold top position until at least 2016.
The key components of Sanofi’s growth include:
- Enzyme replacement therapies from Genzyme
- The blockbuster drugs Cerezyme and Myozyme
Research also suggests that Novartis will be Sanofi’s closest competition over the coming years, with strong sales predicted from Glienya and Tasigna as a result of Dioyan’s loss of patent protection last year.